Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31610455 | 0.93 | HSD17B10 (0.33) | HSD17B10GAANPSR1MAPK8MAPK9 | |
| SCHEMBL31552275 | 0.91 | MAPK8 (0.31) | MAPK8MAPK9MAPK10 | |
| SCHEMBL31048245 | 0.84 | HSD17B10 (0.38) | HSD17B10GAANPSR1CXCL8 | |
| SCHEMBL31552347 | 0.81 | MTNR1A (0.39) | — | |
| SCHEMBL31551897 | 0.80 | PTPN1 (0.31) | — | |
| SCHEMBL31610194 | 0.76 | HSD17B10 (0.38) | HSD17B10GAANPSR1CXCL8 | |
| SCHEMBL31552017 | 0.75 | CACNA1H (0.39) | HSD17B10GAA | |
| SCHEMBL31048312 | 0.74 | POLB (0.30) | — | |
| SCHEMBL31551720 | 0.74 | HSD17B10 (0.47) | HSD17B10GAANPSR1 | |
| SCHEMBL31552285 | 0.74 | HSD17B10 (0.41) | HSD17B10GAANPSR1CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | HSD17B10 3898/4885GAA 2015/4885NPSR1 4835/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | HSD17B10 4743/4885GAA 2385/4885NPSR1 4825/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | HSD17B10 4743/4885GAA 2385/4885NPSR1 4825/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | HSD17B10 2486/4885GAA 3456/4885NPSR1 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.